预防、治疗和根除艾滋病的最佳支柱：恩曲他滨+替诺福韦。

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES Antiviral Therapy Pub Date : 2022-04-01 DOI:10.1177/13596535211067599

Raymond F Schinazi, Dharmeshkumar Patel, Maryam Ehteshami

{"title":"预防、治疗和根除艾滋病的最佳支柱：恩曲他滨+替诺福韦。","authors":"Raymond F Schinazi, Dharmeshkumar Patel, Maryam Ehteshami","doi":"10.1177/13596535211067599","DOIUrl":null,"url":null,"abstract":"The advent of antiretroviral combination therapy has significantly impacted the HIV/AIDS epidemic. No longer a death sentence, HIV infection can be controlled and suppressed using cocktail therapies that contain two or more small molecule drugs. This review aims to highlight the discovery, development, and impact of one such molecule, namely, emtricitabine (FTC, emtriva), which is one of the most successful drugs in the fight against HIV/AIDS and has been taken by over 94% of individuals infected with HIV in the USA. We also pay tribute to Dr. John C. Martin, former CEO and Chairman of Gilead Sciences, who unexpectedly passed away in 2021. A true visionary, he was instrumental in delivering FTC, as part of combination therapy with TDF (tenofovir, viread) to the global stage. As the fight to eradicate HIV marches on, we honor Dr. Martin's legacy of collaboration, achievement, and hope.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":"27 2","pages":"13596535211067599"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.\",\"authors\":\"Raymond F Schinazi, Dharmeshkumar Patel, Maryam Ehteshami\",\"doi\":\"10.1177/13596535211067599\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The advent of antiretroviral combination therapy has significantly impacted the HIV/AIDS epidemic. No longer a death sentence, HIV infection can be controlled and suppressed using cocktail therapies that contain two or more small molecule drugs. This review aims to highlight the discovery, development, and impact of one such molecule, namely, emtricitabine (FTC, emtriva), which is one of the most successful drugs in the fight against HIV/AIDS and has been taken by over 94% of individuals infected with HIV in the USA. We also pay tribute to Dr. John C. Martin, former CEO and Chairman of Gilead Sciences, who unexpectedly passed away in 2021. A true visionary, he was instrumental in delivering FTC, as part of combination therapy with TDF (tenofovir, viread) to the global stage. As the fight to eradicate HIV marches on, we honor Dr. Martin's legacy of collaboration, achievement, and hope.\",\"PeriodicalId\":8364,\"journal\":{\"name\":\"Antiviral Therapy\",\"volume\":\"27 2\",\"pages\":\"13596535211067599\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antiviral Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13596535211067599\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13596535211067599","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

抗逆转录病毒联合疗法的出现极大地影响了艾滋病毒/艾滋病的流行。使用含有两种或两种以上小分子药物的鸡尾酒疗法可以控制和抑制艾滋病病毒感染，而不再是死刑。本综述旨在重点介绍恩曲他滨（FTC，emtriva）这类分子药物的发现、开发和影响，恩曲他滨是抗击艾滋病毒/艾滋病最成功的药物之一，在美国，超过 94% 的艾滋病毒感染者都服用了这种药物。我们还要向 2021 年意外去世的吉利德科学公司前首席执行官兼董事长约翰-马丁博士（Dr. John C. Martin）致敬。作为一位真正的远见卓识者，他在将 FTC 作为 TDF（替诺福韦、韦瑞德）联合疗法的一部分推向全球舞台方面发挥了重要作用。在根除艾滋病的斗争中，我们向马丁博士留下的合作、成就和希望致敬。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.

The advent of antiretroviral combination therapy has significantly impacted the HIV/AIDS epidemic. No longer a death sentence, HIV infection can be controlled and suppressed using cocktail therapies that contain two or more small molecule drugs. This review aims to highlight the discovery, development, and impact of one such molecule, namely, emtricitabine (FTC, emtriva), which is one of the most successful drugs in the fight against HIV/AIDS and has been taken by over 94% of individuals infected with HIV in the USA. We also pay tribute to Dr. John C. Martin, former CEO and Chairman of Gilead Sciences, who unexpectedly passed away in 2021. A true visionary, he was instrumental in delivering FTC, as part of combination therapy with TDF (tenofovir, viread) to the global stage. As the fight to eradicate HIV marches on, we honor Dr. Martin's legacy of collaboration, achievement, and hope.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.